PeptiDream: Consolidated financial results for the six months ended June 30, 2024 [IFRS]
PeptiDream: Announcements of individual stocks: Peptide Dream has received a milestone fee for the second program of peptide-drug conjugates (PDC) joint research and development with Novartis.
PeptiDream: (Revised Disclosure) PeptiDream announces expansion of peptide discovery partnership with Novartis AG.
PeptiDream: Announcements of individual stocks regarding the expansion of partnership with Novartis in peptide drug discovery (progress of disclosure matters).
PeptiDream: Consolidated financial results for the three months ended March 31, 2024 [IFRS]
PeptiDream: PeptiDream announces upward revisions to financial forecasts
PeptiDream: Articles of Incorporation 2023/03/01
PeptiDream: Notice regarding expansion of partnership with Novartis in peptide drug discovery
PeptiDream: Corporate Governance Report 5/4/2024
PeptiDream: (Progress of Disclosure Matters) Notice Regarding Application Results for Tender Offer for Shares Held by the Company
PeptiDream: Notice Regarding PeptiDream’s Participation in Tender Offer
PeptiDream: Notice regarding application for tender offer for shares held by the Company
PeptiDream: Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 [IFRS]
PeptiDream: Corporate Governance Report 19/12/2023
PeptiDream: Consolidated Financial Results for the Nine Months Ended September 30, 2023 [IFRS]
PeptiDream: Notice Concerning Borrowing of Funds
PeptiDream: PeptiDream Announces Update on PDL1 Program Partnered with Bristol-Myers Squibb
PeptiDream: About the PDL1 program with Bristol-Myers Squibb
PeptiDream: Notice of receipt of milestone fees for joint research and development of peptide-drug conjugates (PDC) with PeptiDream and Novartis
PeptiDream: Notice that PeptiDream and Genentech have signed a joint research and development and license agreement on a novel peptide-radionuclide complex (RI-PDC)
No Data
No Data